Verification evidence is still being completed.
PDF / print export
H. Lundbeck A/S
Copenhagen, Denmark
- Verified lead
- Charl van Zyl
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- President and CEO
- 2026 technical specialization
- Brain Research
- Review cycle
- May 2026
- Full address
- Ottiliavej 9, 2500 Valby, Denmark
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Lundbeck executive leadership team page.
- Editorial note
- CNS-focused therapeutics platform with regulated neuropsychiatric portfolio management and commercial pharmaceutical execution.
Brain Research
GMP Certified, ISO 9001
CNS-focused therapeutics platform with regulated neuropsychiatric portfolio management and commercial pharmaceutical execution.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated05 Jun 2026, 01:06
Company profile · Copenhagen, Denmark
H. Lundbeck A/S
Brain Research · Global Supply
Verified 14 Mar 2026 · 4 sources
Commercial
CNS-focused therapeutics platform with regulated neuropsychiatric portfolio management and commercial pharmaceutical execution.
Contact & location
- Website
- lundbeck.com
- Company page
- Lead
- Charl van Zyl (verified ↗)
- Compliance
- GMP Certified · ISO 9001
- Last reviewed
- 14 Mar 2026 (3mo ago)
- Scale
- Global Supply
- Capabilities
- Neuro-science · Psychiatry Research · Protein Engineering
- Founded
- 1915
- Headcount
- 5001-10000
Clinical profileSTATUS: VERIFIED MARCH 2026
Charl van Zyl
President and CEO
Full addressOttiliavej 9, 2500 Valby, Denmark
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Global Supply
Copenhagen, Denmark. Brain Research. Review completed on 14 Mar 2026.
EMA / FDA
GMP Certified, ISO 9001
Brain Research
CNS-focused therapeutics platform with regulated neuropsychiatric portfolio management and commercial pharmaceutical execution.
Editorial note
Lundbeck stays source-backed through the live executive management page, annual reporting surface, and Valby contact disclosure for the Danish headquarters.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Neuro-science
Psychiatry Research
Protein Engineering
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Industrial API Units
Molecular imaging hub
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- VERIFIED ACTIVE 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
14 Mar 2026: Executive identity confirmed via official management disclosure.
14 Mar 2026: Trust review remains in progress.
FAQ
Frequently asked questions
- Where is H. Lundbeck A/S located?
- H. Lundbeck A/S operates from Ottiliavej 9, 2500 Valby, Denmark, Copenhagen, Denmark.
- Who runs H. Lundbeck A/S?
- H. Lundbeck A/S is led by Charl van Zyl, President and CEO. Verified 14 Mar 2026.
- What certifications does H. Lundbeck A/S hold?
- H. Lundbeck A/S is documented under GMP Certified, ISO 9001.
- What does H. Lundbeck A/S do?
- CNS-focused therapeutics platform with regulated neuropsychiatric portfolio management and commercial pharmaceutical execution. Core capabilities: Neuro-science, Psychiatry Research, Protein Engineering.
Editorial context
Related technical briefs
Briefs that name Copenhagen as a covered market or city.